Anti-platelet drugs, pharmacogenomics and stent thrombosis: What’s new?
AbstractStent thrombosis is a catastrophic complication of percutaneous coronary intervention (PCI) and is associated with a mortality of 25 to 40%. The perception that stent thrombosis is very low in all patients has resulted in a lack of adherence to professional guidelines. New data to identify patients at increased risk for stent thrombosis are emerging. Clopidogrel is a prodrug and the activation of clopidogrel is dependent on CY2C19. Numerous alleles of CYP2C19 exist. The allele CYP2CP*2 has been associated with a marked decrease in platelet responsiveness to clopidogrel. Heterozygote carriers of the CYP2C19*2 have a 2.7 fold increased risk and homozygotes a 4.8 fold increased risk of stent thrombosis. Prospective randomised clinical trials will be necessary to determine the efficacy of CYP2C19 genotype directed therapy in evidence-based clinical decision making. Point-of-care platelet-function tests are becoming available and some centres are now performing such tests on their PCI patients. The most recent AHA/ACC /SCAI guidelines recommend testing for clopidogrel responsiveness in patients at high risk of subacute stent thrombosis and recommend increasing the dose of clopidogrel in non-responders.
Copyright (c) 2017 SA Heart Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This journal is an open access journal, and the authorsÂ and journal should be properly acknowledged, when works are cited.
Authors may use the publishers version for teaching purposes, in books, theses, dissertations, conferences and conference papers.Â
A copy of the authors’ publishers version may also be hosted on the following websites:
- Non-commercial personal homepage or blog.
- Institutional webpage.
- Authors Institutional Repository.Â
The following notice should accompany such a posting on the website: “This is an electronic version of an article published in SAHJ, Volume XXX, number XXX, pages XXX–XXX”, DOI.Â Authors should also supply a hyperlink to the original paper or indicate where the original paper (http://www.journals.ac.za/index.php/SAHJ) may be found.Â
Authors publishers version, affiliated with the Stellenbosch University will be automatically deposited in the University’s’ Institutional Repository SUNScholar.
Articles as a whole, may not be re-published with another journal.
Copyright Holder: SA Heart Journal
The following license applies:
Attribution CC BY-NC-ND 4.0